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3-hydroxy-3-methylglutaric aciduria (OMIM 246450) is a rare autosomal recessive inborn of metabolism due to
the deficiency of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase, an enzyme involved both in the
ketogenic pathway and leucine catabolism. Acute decompensations present with lethargy, cianosis, hypotonia,
vomiting and metabolic acidosis with hypoketotic hypoglycemia. We report the case of a 3 days male with
sudden hypoglycemic crisis initially misdiagnosed as a sepsis. HMG-CoA lyase deficiency was achieved through
acyl-carnitines profile (showing a typical increasing of 3-hydroxy-isovaleryl and 3-methylgluraryl carnitines)
and urinary organic acids analysis (disclosing elevation of 3-hydroxy-3-methylglutaric, 3-methyl-glutaconic,
3-methylglutaric and 3-hydroxyisovaleric acids). This case underlines the need of suspecting such inborn metabolic
disorder in cases with hypoglycemia and metabolic acidosis. Acyl-carnitine and urinary organic acids profiles are
essential to achieve a prompt diagnosis of treatable metabolic disorders in order to prevent their acute crisis with
serious or even fatal consequences.Introduction
3-hydroxy-3-methylglutaric aciduria (OMIM 246450) is
a rare autosomal recessive inborn disease due to the
deficiency of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) lyase, an enzyme catalyzing the cleavage of
HMG-CoA to acetyl-CoA and acetoacetic acid, leading to
the common final step of ketogenic pathway and leucine
catabolism, presenting with a typical pattern of urinary or-
ganic acids. The disease was first described by Faull in
1976 and has an estimated prevalence of less than 1 in
100,000 live births [1,2].
It usually presents in the first year of life during a state
of catabolism triggered by a prolonged fasting or intercur-
rent illness. The acute presentation includes vomiting,
hypotonia, lethargy, metabolic acidosis, and non-ketotic
hypoglycemia. Moreover, Reye-like syndrome with acute
liver failure can occur [3,4]. Huge amounts of 3-hydroxy-
3-methylglutaric, 3-methylglutaconic, 3-methylglutaric and
3-hydroxyisovaleiric acids characterize the biochemical
pattern of the disease [3,5].* Correspondence: francesca.santarelli86@gmail.com
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reproduction in any medium, provided the orHere we report the case of a newborn with HMG-CoA
lyase deficiency presenting at 3 days of life with a sudden
severe hypoglycemic crisis misdiagnosed with sepsis.Case report
We describe the case of a male newborn, born at term
from non-consanguineous parents by vaginal delivery,
with an APGAR scores 10 and 10 at 5 and 10 minutes,
respectively, and antropometric parameters at the 50°
percentile. Since the mother’s bacteriological vaginal
smear was positive for Streptococcum Beta Agalactiae,
the mother underwent a complete intrapartum antibiotic
prophylaxis (ampicillin and sulbactam 3 g five hours be-
fore delivery, then 1.5 g one hour before delivery). The
discharge was carried out on the third day after delivery.
Four hours after being discharged, the infant was admit-
ted to a primary care hospital for poor suckling and sud-
den multiple episodes of hypotonia, oculogyration
associated with hypothermia, progressive tachypnoea
and respiratory failure.
Initial laboratory investigations revealed white blood cell
count 14,140/μl, c-reactive protein of 0.33 mg/dl and
severe hypoglycemia (3 mg/dl, reference range 70–110).
Arterial blood gas analysis revealed a partially correctedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Santarelli et al. Italian Journal of Pediatrics 2013, 39:33 Page 2 of 5
http://www.ijponline.net/content/39/1/33metabolic acidosis (blood pH 7.226, pCO2 41.7 mmHg,
pO2 47.2 mmHg, bicarbonate 16.9 mEq/l, base ex-
cess −10.3 mEq/l). Sepsis was initially suspected and the
infant was put on endovenous hydratation (balanced
pediatric solution for endovenous infusion – glucose
content 55 g/L - 80 ml/kg/day, glucose infusion
3 mg/kg/min) and treated with antibiotic therapy
(Ampicillin 25 mg/kg b.w. every 6 hours and Genta-
micin 4 mg/Kg/day for 4 days).
During next four hours, the patient developed a pro-
gressive dyspnoea with worsening of the metabolic acid-
osis, so he was transferred to our department, where
metabolic workup was carried out, revealing mild
hyperammonaemia (63 μmol/L; reference range 11–32),
hyperlactataemia (3.14 mmol/L; reference range 0.22-2.22)
and moderate hypertransaminasemia (aspartate amino-
transferases 52 U/l, alanine aminotransferases 39 U/L;
reference range10-37). No ketone bodies were detected in
urines.
Glycaemic levels were raised up by endovenous infusion
but not normalized, measuring 30 mg/dl. Hormonal panel
including cortisol (352.7 nmol/L, reference range 220.7-
689.7), adrenocorticotropic hormone (32 ng/ml, reference
range 7.9-66.1 ng/ml ), growth hormone (12 ng/ml, refer-
ence range 1–20 ng/ml), glucagon (102 ng/L, reference
range 50–150 pg/ml), insulin (83.3 pmol/L, reference
range 41.6-159.7) was normal. Imaging (cerebral, heartC5-OH
C6
Figure 1 Acyl-carnitine profile revealing a typical increasing in 3-Hyd
(C6-DC) concentrations.and abdominal ultrasound scan) did not reveal any evi-
dence of heart, renal or cerebral malformations.
The patient was treated with endovenous 10% glucose
administration (80 ml/kg/day, glucose amount 6.1 mg/kg/
min) and bicarbonate (NaHCO3 total amount 1.6 mEq)
until the recovery from hypoglycaemia and acidosis.
The evidence of severe hypoglycaemia accompanied by
acidosis and hyperammonaemia prompted the differ-
ential diagnosis between beta-oxidation disorders and
gluconeogenesis defects. A second level metabolic screen-
ing was then performed, including plasma aminoacids,
bloodspot acyl-carnitine and urine organic acid analysis.
Bloodspot acyl-carnitine assay showed significant increase of
C5-OH acyl-carnitine (corresponding to the isobar com-
pounds 2-hydroxy/3-hydroxy-isovaleryl-, 3-methylcrotonyl-,
2methyl-3hydroxy-butyryl- or 3-methylglutaconyl- carnitine)
and of C6-DC acylcarnitine (3-methylglutaryl- or adipoyl –
carnitine) (Figure 1). The simultaneous increase of these
two markers led to identify them as 3-hydroxy-isovaleryl
carnitine (7.78 μmol/l, reference range 0.00-0.40) and
3-methylglutaryl carnitine (0.76 μmol/l, reference range
0.00-0.14), respectively.
Urine organic acid analysis showed high excretion of
3-hydroxy-3-methyl-glutaric acid and 3-methyl-crotonyl-
glycine (Figure 2; Table 1) confirming the bloodspot
acylcarnitine abnormalities. This pattern led to the final
diagnosis of HMG-CoA lyase deficiency.DC













Figure 2 Urinary organic acids profile with evident increasing in 3-hydroxy-isovaleric, 3-methylglutaric, glutaric, 3-methyl-glutaconic,
3-hydroxy-3-methyl-glutaric acids and 3-methyl-crotonyl-glicine.
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stopped and maintenance therapy was based on a low
fat and protein diet with frequent meals in order to
avoid hypoglycemia. Moreover, a carnitine supplement
(400 mg/day) was started.
Four months after diagnosis, the patient presented an-
other severe hypoglycemic episode after a viral infection
which was solved out within 36 hours through hydration
and glucose infusion. In spite of the severe episode of
hypoglycaemia, no neuropsychomotor impairment is
present to date. He is now twenty-two months old with
normal development and growth.Discussion
3-hydroxy-3-methylglutaric aciduria is a rare disease
characterized by the lack of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG CoA) lyase (HL), an enzyme pre-
senting into two different isoforms: the first one, located
in mithocondria, catalyzes the conversion of HMG-CoA
into acetoacetate and acetyl-CoA, while the second one,
expressed in peroxisomes, is hypothesized to be involvedTable 1 Characteristic urinary organic acids profile with evide
glutaric, 3-methyl-glutaconic, 3-hydroxy-3-methyl-glutaric aci






3-methyl-glutaconic 4166.4in cholesterol synthesis and long-chain fatty acid degrad-
ation [2].
HL deficiency leads to the a reduced ability to
synthesize ketones, which are a primary energy source
for brain when glucose is not available and which are
employed, in newborn period and suckling, as substrates
for lipid synthesis in myelin [2].
HMG CoA Lyase deficiency usually presents with acute
metabolic crisis in the early neonatal period, being 60-70%
of cases reported during the first year of life and thirty
percent of them occuring between the second and the fifth
day of life [1,2]. Acute crisis, usually triggered by catabol-
ism induced by fasting , illness, stress or excessive physical
exercise, include hypothermia, vomiting, diarrhea, dehy-
dration, hypotonia, cianosis, apnea and metabolic acidosis
with hypoketotic hypoglycemia potentially progressing to
coma. Patients can also develop a Reye-like syndrome
with hyperammonemia, hepatomegaly and encelopathy
[3,4]. Late-onset forms have been described, characterized
by the possible development of hepatic steatosis, pancrea-
titis, white matter alterations (due both the damage
resulting from recurrent hypoglycemic episodes and bynt increasing in 3-hydroxy-isovaleric, 3-methylglutaric,
ds and 3-methyl-crotonyl-glicine







Table 2 Differential diagnosis of hypoglycaemia
Hypoketotic hypoglycaemia Ketotic hypoglycaemia
Low free fatty acids High free fatty acids
Hyperinsulinism FAO defects Sepsis
Organic acidurias
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dilated cardiomyopathy. This latter was hypotesized to
result both from the lack of ketones as energy source, both
from impaired ketogenesis, intracellular fatty acid accu-
mulation and secondary carnitine deficiency, due to its
esterification to 3-methylglutarylcarnitine. L-carnitine
supplementation, by the increasing the urinary excretion
of toxic metabolites, is considered essential in order to
prevent the development of cardiomyopathy. It’s also
thought to manage the transport of fatty acids to the
mithocondria for oxidation and to be a free radical scaven-
ger and a cofactor in the oxidation of long-chain fatty
acids [2,4-6].
After the first year of life patients usually show a
prolonged resistance to fasting and most of adults are
symptoms free.
Our patient presented with hypoglycemia and acidosis
leading to coma. First assessments posed the wrong
hypothesis of sepsis, but the persistence of metabolic
acidosis, together with further investigations excluding any
renal, heart or cerebral pathology and revealing hype-
rammonaemia, hyperlactataemia and hypoketonemia, led
to suspect an inborn metabolic disease. As it should always
be done in the differential diagnosis of hypoglycemic crisis,
congenital endocrine deficiencies were ruled out by finding
normal concentrations of the hormones involved in glu-
cose homeostasis (cortisol, adrenocorticotropic hormone,
growth hormone, glucagon, insulin) [7].
Hypoketotic hypoglycemia is usually present in fatty acid
oxidation defects, but it’s also associated with hyperinsulin-
ism, endocrine deficiencies and ketogenesis defects. Deter-
mination of free fatty acids levels should be useful in order
to differentiate these conditions. In reverse, ketoacidosis is
a typical finding in organic acidurias (such as maple syrup
urine disease, propionic aciduria, methylmalonic aciduria,
isovaleric aciduria), gluconeogenesis defects (such as
fructose-1, 6-bisphosphatase, pyruvatecarboxylase, phos-
phoenolpyruvate carboxykinase deficiencies), glycogenoly-
sis, ketolysis and respiratory chain defects (Table 2).
However, it’s essential to perform acyl-carnitines and
urinary organic acids profile in order to achieve a final
diagnosis and to differentiate among fatty acid oxidationand ketogenesis defects (Glutaric aciduria type II, car-
nitine palmitoyltransferase II, carnitine acylcarnitine
translocase, deficiency of very-long-chain acyl CoA
dehydrogenase , medium-chain acyl-CoA dehydrogen-
ase, 3-OH long-chain acyl CoA dehydrogenase, HMG-
CoA lyase and HMG-CoA synthase).
Conclusion
This case stresses the need for prompt recognition of
this rare metabolic disorder in any case of newborn
hypoglycemia with hypoketonemia. Acyl-carnitine and
urinary organic acids profile are essential in order to
achieve a quick diagnosis and to differentiate HL defi-
ciency from organic acidemias and other fatty acid oxi-
dation defects.
Furthermore, implementation of newborn screening
procedures by tandem mass-spectrometry probably
would have not avoided the acute crisis in our case, as
the newborn screening results would have been available
only after the discharge of the child. Routine newborn
discharge within two or three days after delivery exposes
apparently healthy children to the risk of development
metabolic acute crisis despite newborn screening
procedures.
Finally, it’s essential to suspect a metabolic inborn disease
in every case of hypoglycaemia associated with metabolic
acidosis. Acyl-carnitine and urinary organic acids profiles
are essential to achieve a prompt diagnosis of all dietary
treatable metabolic disorders in order to prevent their acute
crisis with serious or even fatal consequences.
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